Suchergebnisse - "Wurtz, Anna"

PubPharm (20)

1

ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts

enthalten in: Cancer research | 2024

von Hu, B. | Wiesehöfer, M. | de Miguel, F. | +17

2

Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024

von Stockhammer, P. | Grant, M. | Wurtz, A. | +13

3

Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer

enthalten in: Cancer cell | 2023

von de Miguel, F. | Gentile, C. | Feng, W. | +23

4

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Grant, M. | Aredo, J. | Starrett, J. | +18

CommentIn: Transl Lung Cancer Res. 2024 Jan 31;13(1):195-198. - PMID 38404992

5

Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo

enthalten in: bioRxiv.org | 2021

von Foggetti, G. | Li, C. | Cai, H. | +17

6

Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo

enthalten in: Cancer discovery | 2021

von Foggetti, G. | Li, C. | Cai, H. | +17

7

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2019

von Truini, A. | Starrett, J. | Stewart, T. | +12

CommentIn: Clin Cancer Res. 2020 Jan 15;26(2):518-519. - PMID 31941684

8

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas : Clinical Outcomes

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019

von Marcoux, N. | Gettinger, S. | O'Kane, G. | +18

9

Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2018

von Gettinger, S. | Wurtz, A. | Goldberg, S. | +9

CommentIn: J Thorac Oncol. 2018 Jun;13(6):741-744. - PMID 29793645

10

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

enthalten in: Cancer discovery | 2017

von Gettinger, S. | Choi, J. | Hastings, K. | +23